Almac Group appoints Dr Sheryl Foster as Vice President of Quality

May 28, 2019

Craigavon, UK, 28 May 2019Almac Sciences, a member of the Almac Group, today announced the appointment of Dr Sheryl Foster to the position of Vice President of Quality, reporting to Managing Director & President, Dr Stephen Barr.

Dr Foster will assume overall responsibility for global Quality Assurance across the Almac Sciences’ sites across Europe and the US driving the strategy and policy for quality excellence.

In addition to her direct quality responsibilities, Sheryl will also participate as a member of the Almac Sciences’ senior leadership team assisting with strategy development and implementation aimed at driving further growth and of the global business.

With extensive quality experience gained over the last 20+ years Sheryl is a highly respected quality professional. Her most recent roles were as a Product Quality leader for GSK in Singapore and most recently as Director of Quality for Avara’s API Manufacturing site in the UK. Prior to this, Sheryl worked in a number of quality roles in the UK, China and Australia.

Following this appointment, Almac Sciences’ current VP Quality Operations, Dr John Robson, will focus his attention on its Analytical services offering as the VP of Analytical Operations.

Dr Barr, commented on Sheryl’s appointment: “Sheryl is a highly experienced quality manager with a wealth of expertise, understanding and industry insight which will prove instrumental in the development of our business as we continue to expand globally. We are delighted to welcome her to our senior management team.”


About Almac Group
A unique culture delivering exceptional solutions

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5600 highly skilled personnel across 18 facilities including Europe, the US and Asia.

The company has a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.

To keep up to date with latest news, follow Almac Group on Twitter and LinkedIn.


Back to news